📖 🔥 New online #firmonertinib in EGFR #PACC-mut NSCLC. @Cancer_Cell 👉 Firmonertinib has a trifluoroethoxy group, which enhances its potency against EGFR PACC mutation 👉 68% response rate with firmonertinib 240 mg daily. Median progression-free survival of 16.0 months at 240 mg. 👉 47% intracranial response rate among patients with baseline brain metastases. @EGFRResisters @Exon20Group @lungoncdoc @riess_md

😜 Are we ready for the era of #PD1×VEGF #bispecific immunotherapy? 📖 Now online in #LancetOncology: #HARMONi — #ivonescimab plus chemotherapy in patients with #EGFR-mutant #NSCLC after progression on EGFR TKI therapy. 👉 First global randomized phase 3 study of a PD1×VEGF bispecific antibody N = 438, with 23% of patients enrolled in the United States 👉 Progression-free survival: 6.8 vs 4.4 months, HR 0.52 👉 Overall survival: 16.8 vs 14.0 months, HR 0.79 👉 Encouraging evidence of protection against CNS progression 💡 HARMONi represents an important step in evaluating the potential of simultaneously targeting PD-(L1)1 and VEGF. I hope this will be the first of many positive global studies exploring PD-(L)1 × VEGF approaches for patients with lung cancer and other solid tumors. lnkd.in/gUbwUxTb ❤️ my global col-investigators, @Tony_Calles @delvysra @MNagasaka @DrSanjayPopat @nicogirardcurie, Drs. Passaro, Cappuzzo, Zhang, and many others ❤️

📖 Now online @CD_AACR 🔥 👉 The oncogenic #EGFR–SHC1 #fusion drives hashtag#lungcancer through dual activation of the N-terminal EGFR kinase domain and C-terminal SHC1 phosphorylation sites. This biology requires combined inhibition of both EGFR and SRC-family kinases to achieve effective clinical control. 👉 Most importantly, this represents a novel fusion activation mechanism: SHC1 acts not merely as a facilitating #fusion partner, but as a true #collaborating partner in oncogenesis: a previously unrecognized mechanism with direct therapeutic implications. 👉 Could similar cooperative signaling by fusion partners help explain de novo or early resistance in other fusion-driven cancers? 😜 doi.org/10.1158/2159-8290.CD… @ElizSMcKenna and Jurgen Wolf (University Hospital Cologne, Germany)

This is the amazing fifth @DAVAOnc Lung Summit meeting. 60% new faculties, topics were spanning from novel mechanistic discoveries to lastest FDA decsions, in all areas of #HNSCC and #NSCLC. @LaurenByersMD @fred_hirsch @maraantonoff @DasMillie11

📖 🔥New online from our group at @UTMDAnderson on ultra-precision oncology in #lungcancer 👉 Analysis from over 22,000 #EGFR-mutant tumor samples identified #PACC mutations in 12% of cases (A) 👉 While classical and #Ex20 mutations more commonly occur as single mutations, PACC mutations are more frequently (66%) observed as compound mutations (B). 👉 PACC/PACC and PACC/classical-like compound mutations function biologically similar to single PACC mutations, NOT classical mutations (C) 👉 Compound PACC mutations demonstrate greater sensitivity to EGFR TKIs than single PACC mutations (D) ⚡ 💡 Largest #EGFR mutation landscape in a Western population. ⚡ 💡 #Compound EGFR PACC Eare biologically analogous to #single PACC. ⚡ 💡 Important insights for drug development of next-generation EGFR TKIs.

🎀 💗Strong team work! BH-30643 represents a next-generation #EGFR #TKI that is potentially 10x more potent than osimertinib, strong CNS penetrance, and able to overcome on-target EGFR resistance! @Exon20Group @EGFRResisters @UTMDAnderson @mollylisc @geoff_oxnard @jjeancui

Kicking off #ASCO26 by celebrating the Giants of Cancer Care induction ceremony! 🎀Congratulations to Dr. Wakelee @HwakeleeMD for Thoracic Malignancy 🎀Congratulations to Dr. Kopetz @skopetz for GI Maligancy @UTMDAnderson 🎀Congratulations to Dr. William Wierda for Leukemia 💐💐💐With friends @drgandara @JoelNealMD @riess_md

At #ASCO26, the @UTMDAnderson Thoracic Medical Oncology Department will deliver an incredible 9 oral presentations💐💐💐 highlighting advances across ##EGFR, #HER2, #KRAS, #KEAP1/STK11, #SCLC, IO, #peri-operative, all lung cancer subgroups. For perspective, thoracic medical oncologists from China have 16 oral presentations. 👩‍⚕️🧑‍⚕️ 👩‍🔬🧑‍🔬Our entire MDA Thoracic team @FSkoulidis @NIVokes @LaurenByersMD @lungoncdoc Drs. Heymach, Cascone, Zhang, @mvnegrao @YYElamin @AnneTsao2 are deeply proud and excited 😀to help shape the future of lung cancer research and patient care alongside outstanding collaborators and industry partners.

Dr. Stephen Liu @StephenVLiu gave the insightful vision on how #AI will impact our clinic, including patient care, physician wellness, clinical research and drug development. @StephenVLiu at #RomeLung26 Thank you @FedericoCappuz1 @BRicciutiMD for organizing this fantastic #lung #summit

Strongly support my @UTMDAnderson colleague Dr. Hussein Tawbi @HTawbi_MD for #SITC Director election ❤️💐 👉Hussein is an internally renowned #physicianscientist immune-oncology leader who has helped redefine what immunotherapy can achieve in some of the most challenging clinical settings. 👉His leadership of the CheckMate 204 study established the role of nivolumab + ipilimumab in melanoma brain metastases, a historically underserved population, 👉He led RELATIVITY-047 which enabled the approval of nivolumab + relatlimab, introducing LAG-3 as a new checkpoint target. His voice and compassion, grounded in patient care and scientific rigor, would be an outstanding addition to the #SITC Board as we navigate the next era of immunotherapy innovation. 🚀

Strongly support Dr. Zhen Su @MyOncology , my friend, colleague, and mentor for SITC Director election. 💪❤️ 👉When he served as the global oncology leader at #MerckKGaA/#EMDSerono, he translated complex immune biology to approvals, then becaome impactful therapies for patients. He has multiple global approvals across agents such as #avelumab, #tepotinib, #erbitux and others. 👉Now as the CEO of #Marengo, he is a true architect with vision, taking first-in-class T-cell agonist programs from platform stage into human studies and secured strong partnerships. 👉Zhen has been a long-standing contributor to the #immuno-oncology community, including leadership roles within #SITC. His vision of bringing early discovery to global commercialization will continue shaping the development of next generation immunotherapies. 🚀

Appreciate @StephenVLiu and @CharuAggarwalMD organizing a fantastic US Focus Meeting Lung Cancer. I discussed 1L EGFR-mut NSCLC landscape evolution with friends and colleagues @riess_md @JuliaRotow @JustinGainor @ShirishGadgeel @BalazsHalmosMD. Nashville is a charming city with such fun characters.

😊 🩷 Nice to see friends and colleagues in the #lungcancer community from different continents at #ELCC26. @caliraf @Alfdoc2 @HHorinouchi @MartinReck2 @Tony_Calles @DoctorJSpicer @fred_hirsch @bensolomon1 @NReguart @BalazsHalmosMD @BrendonStilesMD @mollylisc @karenkellymd @ThomasW35874311 @NadalErnest @DrSanjayPopat 😊 🩷 Safe travels ✈️ 💐💐💐Grateful for the wonderful organization between @IASLC and @esmo for an impactful and fun #ELCC26.

We discussed innovations in ADCs to overcome topo-payload ADC resistance. 🔥Novel payloads include dual-cytotoxic, radioligands, immune stimulators or engagers, oligonucleotides (siRNA), degraders, and small molecule inhibitors. 🤣 Yes, "Any-Drug-Conjugates (ADC)" ❤️💡

Honored to be delivering two educational lectures at 🔜 #ELCC26 @myESMO🇩🇰 in Copenhagen. 📍 March 26. 👉Beyond traditional ADCs: Advances in targeting, conjugation, payload design, and emerging modalities 📍 March 28 👉Mechanisms of resistance: Lessons from EGFR-mutant and ALK-rearranged NSCLC 💐Grateful to the conference chairs @DrSanjayPopat @APassaroMD for your excellent work on organizing #ELCC26. 💗Looking forward to great discussions and connecting with global colleagues @HHorinouchi @ThomasW35874311 @Alfdoc2 @caliraf @tnewsomdavis @YYElamin @lungoncdoc